CERRI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.889
EU - Europa 13.001
AS - Asia 9.348
SA - Sud America 1.368
Continente sconosciuto - Info sul continente non disponibili 383
AF - Africa 210
OC - Oceania 30
Totale 46.229
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.257
IT - Italia 6.514
SG - Singapore 3.013
GB - Regno Unito 2.420
CN - Cina 2.193
BR - Brasile 1.028
HK - Hong Kong 1.024
VN - Vietnam 972
SE - Svezia 777
DE - Germania 700
BD - Bangladesh 584
FR - Francia 513
RU - Federazione Russa 409
FI - Finlandia 381
UA - Ucraina 312
CA - Canada 282
NL - Olanda 259
TR - Turchia 254
KR - Corea 253
IN - India 231
ID - Indonesia 194
JP - Giappone 138
MX - Messico 131
BG - Bulgaria 130
AR - Argentina 106
IE - Irlanda 98
IQ - Iraq 76
ES - Italia 70
PL - Polonia 68
PK - Pakistan 62
ZA - Sudafrica 58
EC - Ecuador 51
BE - Belgio 50
CR - Costa Rica 48
CO - Colombia 44
VE - Venezuela 40
AT - Austria 35
RO - Romania 35
AE - Emirati Arabi Uniti 34
CL - Cile 33
IL - Israele 33
LT - Lituania 32
MY - Malesia 29
MA - Marocco 28
CH - Svizzera 27
SA - Arabia Saudita 27
EG - Egitto 24
TW - Taiwan 24
HN - Honduras 23
JO - Giordania 23
PE - Perù 23
JM - Giamaica 22
AU - Australia 21
NI - Nicaragua 20
TN - Tunisia 20
KE - Kenya 19
PH - Filippine 19
DZ - Algeria 18
IR - Iran 18
PY - Paraguay 18
UZ - Uzbekistan 18
AZ - Azerbaigian 17
CZ - Repubblica Ceca 17
NP - Nepal 16
SV - El Salvador 16
TH - Thailandia 16
DK - Danimarca 15
GT - Guatemala 15
RS - Serbia 14
SC - Seychelles 14
UY - Uruguay 14
AL - Albania 13
DO - Repubblica Dominicana 13
EE - Estonia 13
LV - Lettonia 13
PR - Porto Rico 13
TT - Trinidad e Tobago 13
HR - Croazia 12
HU - Ungheria 12
CW - ???statistics.table.value.countryCode.CW??? 10
PT - Portogallo 10
GP - Guadalupe 9
NZ - Nuova Zelanda 9
BO - Bolivia 8
EU - Europa 8
GE - Georgia 8
SN - Senegal 8
BB - Barbados 7
BH - Bahrain 7
KG - Kirghizistan 7
KZ - Kazakistan 7
NO - Norvegia 7
SI - Slovenia 7
SY - Repubblica araba siriana 7
GR - Grecia 6
OM - Oman 6
BY - Bielorussia 5
ET - Etiopia 5
KW - Kuwait 5
LB - Libano 5
Totale 45.770
Salva come PNG Salva come JPEG
Città #
Ashburn 2.671
Singapore 2.029
Santa Clara 1.801
Fairfield 1.689
Southend 1.635
San Jose 1.357
Hong Kong 992
Woodbridge 992
Chandler 947
Council Bluffs 851
Houston 759
Seattle 625
Wilmington 547
Cambridge 516
Hefei 514
Milan 512
Beijing 490
Dearborn 469
Ann Arbor 444
Nyköping 444
Jacksonville 432
Rome 414
London 369
New York 369
Los Angeles 297
Ho Chi Minh City 269
Helsinki 261
The Dalles 261
Modena 253
Hanoi 246
Seoul 208
Chicago 199
San Diego 185
Dallas 155
Naples 155
Bologna 149
Jakarta 145
Princeton 125
Sofia 124
Buffalo 119
Florence 118
Lauterbourg 117
Columbus 113
São Paulo 107
Tokyo 106
Eugene 105
Palermo 105
Shanghai 99
Munich 95
Izmir 93
Moscow 93
Phoenix 87
Bari 85
Orem 85
Redwood City 84
Salt Lake City 83
Boardman 74
Toronto 73
Catania 69
Dublin 68
Turin 68
Atlanta 65
Frankfurt am Main 65
Reggio Emilia 59
Montreal 57
Bremen 56
Mexico City 50
Brooklyn 49
San Francisco 48
Verona 47
Da Nang 46
Genoa 44
Guangzhou 41
Warsaw 41
Brussels 40
Charlotte 40
North Bergen 40
Chennai 38
Denver 38
Elk Grove Village 37
Cagliari 36
Dong Ket 36
Padova 35
Parma 35
Haiphong 34
Nuremberg 34
San José 34
Poplar 32
Rio de Janeiro 32
Tampa 32
Miano 30
Boston 29
Turku 29
Baghdad 28
Brescia 28
Manchester 28
Philadelphia 28
Redondo Beach 28
Falls Church 27
Lahore 27
Totale 28.469
Salva come PNG Salva come JPEG
Nome #
INTERSTIZIOPATIA POLMONARE NON CLASSIFICABILE O SECONDARIA A CONNETTIVITE INDIFFERENZIATA. IMPORTANZA E DIFFICOLTÀ DI UNA DIAGNOSI DIFFERENZIALE. 3.907
Malattie infiltrative diffuse del polmone 1.274
Multidrug-resistant tuberculosis outbreak in an Italian prison: Tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays 825
Non-steroid agents for idiopathic pulmonary fibrosis 530
Radiologic classification of usual interstitial pneumonia in rheumatoid arthritis-related interstitial lung disease: correlations with clinical, serological and demographic features of disease 503
Acute exacerbation of Idiopathic Pulmonary Fibrosis: lessons learned from the Acute Respiratory Distress Syndrome 455
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 452
Analysis of pulmonary sounds for the diagnosis of interstitial lung diseases secondary to rheumatoid arthritis 443
Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: The InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device) 430
Performance of tests for latent tuberculosis in different groups of immunocompromised patients 428
Effectiveness of pulmonary rehabilitation in patients with INTERSTITIAL LUNG DISEASE of different etiology: a multicenter prospective study 399
Proteomics Analysis of Formalin-Fixed Paraffine-Embedded Tissue Reveals Key Proteins Related to Lung Dysfunction in Idiopathic Pulmonary Fibrosis. 391
Morbidity and Mortality in Patients with Idiopathic Pulmonary Fibrosis Undergoing Diagnostic Surgical Lung Biopsy 384
Comparison of the tubercolin skin test and the ellispot blood test for the diagnosis of latent tuberculosis infection in pre-transplant dialysis patients 382
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments 380
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 377
INTERSTITIAL LUNG DISEASE RELATED TO RHEUMATOID ARTHRITIS. WHAT DO WE DON’T KNOW? THE LIRA STUDY (LUNG INVOLVEMENT IN RHEUMATOID ARTHRITIS) 377
Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. 371
Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease 368
NEW PERSPECTIVES IN DIAGNOSIS OF INTERSTITIAL LUNG DISEASE RELATED TO RHEUMATOID ARTHRITIS. VALIDATION STUDY OF AN ELECTRONIC STETHOSCOPE AND AD HOC SOFTWARE FOR DETECTION OF PULMONARY CRACKLES 365
Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review 358
Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature 352
Emerging drugs for idiopathic pulmonary fibrosis. 350
Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement 347
Ventilatory support and mechanical properties of the fibrotic lung acting as a “squishy ball” 345
Expression of HOXB7 in the lung of patients with idiopathic pulmonary fibrosis: a proof of concept study. 344
Serial Ultrasound Assessment of Diaphragmatic Function and Clinical Outcome in Patients with Amyotrophic Lateral Sclerosis. 343
Molecular mechanisms and cellular contribution from lung fibrosis to lung cancer development. 342
Use of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Case Study 340
Prevalence Of Subclinical Liver Fibrosis Among Patients With Idiopathic Pulmonary Fibrosis 339
Pulmonary stretch and lung mechanotransduction: Implications for progression in the fibrotic lung 339
Role Of The QFT-IT Assay For The Diagnosis Of Latent Tuberculosis Infection Among Adult Immigrants 338
Management of idiopathic pulmonary fibrosis. 336
Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. 335
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis. 330
Fibrotic idiopathic interstitial lung disease: the molecular and cellular key players. 329
HRCT Patterns Of Usual Interstitial Pneumonia In Rheumatoid Lung 328
Rifabutin for treating pulmonary tuberculosis. 326
Etiology and Level of Lung Derangement Do Not Affect the Beneficial Effect of Pulmonary Rehabilitation in Patients with Interstitial Lung Diseases 323
Inspiratory effort and respiratory mechanics in spontaneously breathing patients with acute exacerbation of idiopathic pulmonary fibrosis: a retrospective matched control study. 323
Lung fibrosis, bone marrow fibrosis and liver cirrhosis: A Short Telomere Syndrome or a casual association? 322
A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM) 322
Best supportive care for idiopathic pulmonary fibrosis: Current gaps and future directions 322
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline 318
Interstitial pneumonia with autoimmune features: A single center prospective follow-up study 318
Home Oxygen Saturation Monitoring And Quality Of Life Evaluation In Patients With Idiopathic Pulmonary Fibrosis: Preliminary Results From A Prospective Multicenter Trial 317
Sarcoidosis: challenging diagnostic aspects of an old disease. 315
Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature 311
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 311
Pulmonary fibrosis and the many faces of UIP 309
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report 306
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis 306
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis 306
Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy 304
Clinical differences in sarcoidosis patients with and without lymphoma: a single-center retrospective cohort analysis. 304
Management of Idiopathic Pulmonary Fibrosis 303
AB1157 VALIDATION OF VECTOR (VELCRO CRACKLES DETECTOR) FOR THE DIAGNOSIS OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH CONNECTIVE TISSUE DISEASES 301
Quantiferon-TB Gold In-Tube Tests In Hospital Health Care Workers: A Five Years Experience 293
Ultrasound assessed Diaphragm Impairment is a Predictor of Outcomes in Acute Exacerbation of Chronic Obstructive Pulmonary Disease undergoing Non-Invasive Ventilation. 292
Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TB assay 290
UNCLASSIFIABLE INTERSTITIAL LUNG DISEASE OR UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE? A CHALLENGING DIFFERENTIAL DIAGNOSIS 290
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis 287
Levels Of Fibulin-1 In The Lung And Serum Are Increased In Fibrotic Interstitial Lung Disease 285
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust 283
Real-life comparison of Pirfenidone and Nintedanib in patients with Idiopathic Pulmonary Fibrosis: a 24-month assessment. 282
Copd, pulmonary fibrosis and ilas in aging smokers: The paradox of striking different responses to the major risk factors 278
Smoking-related interstitial lung disease 276
Genetic commonality between inflammatory bowel disease and sarcoidosis: the beginning of the end or the end of the beginning? 276
The encaged lung: rapidly progressive idiopathic pleurisy. 276
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis 275
Empoyment of the ELISPOT blood test for the diagnosis of latent tuberculosis infection in dialysis patients awaiting renal transplantation 274
Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicenter retrospective study 274
Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review 273
Validation of a Method for Automatic Detection of Lung Sounds in Fibrotic Interstitial Lung Disease 271
INTERSTITIAL LUNG DISEASE IS ASSOCIATED TO INFECTIONS OF LOWER RESPIRATORY TRACT IN IMMUNOCOMPROMISED RHEUMATOID ARTHRITIS PATIENTS 270
Identification Of Potential Candidate Biomarkers In Lymphangioleiomyomatosis Using ITRAQ Proteomic Technology 269
The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease 268
Pulmonary Carcinosarcoma Arising in the Framework of an Idiopathic Pulmonary Fibrosis 265
The big clinical trials in idiopathic pulmonary fibrosis. 264
Repeated Quantiferon-TB Gold In-Tube Tests In Routine Clinical Practice: A Five Years Experience 264
Challenges in idiopathic interstitial lung disease 263
Inappropriatezza prescrittiva dell'ossigenoterapia domiciliare a lungo termine 263
Biological effects of COVID-19 on lung cancer: can we drive our decisions? 261
RHEUMATOID ARTHRITIS RELATED INTERSTITIAL LUNG DISEASE. RADIOLOGICAL PATTERNS AND CORRELATIONS WITH CLINICAL, SEROLOGICAL AND DEMOGRAPHIC FEATURES OF DISEASE 260
Impact of Mesenchymal Stromal/stem Cell Infusions on Circulating Inflammatory Biomarkers in COVID-19 Patients: Analysis of a Phase I-IIa Trial. 254
AB0472 PRIMARY SJOGREN SYNDROME ASSOCIATED INTERSTITIAL LUNG DISEASE: FEATURES, TREATMENT AND OUTCOME OF A MONOCENTRIC COHORT 254
Predicting Mortality in Patients with Rheumatoid Arthritis Related Interstitial Lung Disease: Expanding The GAP Model 253
Dissecting the role of mesenchymal stem cells in idiopathic pulmonary fibrosis: cause or solution? 252
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis 251
Janus-faced amiodarone-induced pneumopathy 248
Human mucosal associated invariant T cells detect bacterially infected cells 246
Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis 240
Differences between acute exacerbations of idiopathic pulmonary fibrosis and other interstitial lung diseases. 239
Physiological effects of lung protective ventilation in patients with lung fibrosis and usual interstitial pneumonia pattern versus primary ARDS: a matched-control study. 238
Interstitial lung disease is associated to infections of lower respiratory tract in immunocompromised rheumatoid arthritis patients 238
Tubercolosi 237
Erratum: Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature (Journal of Thoracic Disease (2019) 11 (1621-1628) DOI: 10.21037/jtd.2019.03.28) 230
CHARACTERIZATION OF ANTI-MPO POSITIVE INTERSTITIAL LUNG DISEASE. CLINICAL-SEROLOGIC AND RADIOLOGIC FEATURES AND SURVIVAL 225
Tofacitinib for the Treatment of Severe Interstitial Lung Disease Related to Rheumatoid Arthritis 225
Genetic testing in diffuse parenchymal lung disease 224
Totale 36.379
Salva come PNG Salva come JPEG
Categoria #
all - tutte 159.812
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 159.812
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.269 0 0 0 210 142 187 146 156 332 226 495 375
2022/20233.613 349 340 237 313 360 424 166 381 428 144 260 211
2023/20243.644 172 201 235 342 471 373 470 407 127 145 305 396
2024/20257.344 315 177 220 503 1.353 982 670 458 755 337 667 907
2025/202613.480 870 496 975 1.429 1.881 905 1.649 717 1.299 1.206 1.175 878
2026/20274.478 496 1.054 1.201 1.727 0 0 0 0 0 0 0 0
Totale 46.229